Blueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland Sells 1,446 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland sold 1,446 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the transaction, the chief executive officer now owns 149,378 shares in the company, valued at approximately $16,467,430.72. This represents a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Kate Haviland also recently made the following trade(s):

• On Friday, November 29th, Kate Haviland sold 2,353 shares of Blueprint Medicines stock. The shares were sold at an average price of $96.60, for a total transaction of $227,299.80.

Blueprint Medicines Stock Performance

BPMC traded up $4.55 during trading on Thursday, hitting $115.63. The stock had a trading volume of 1,479,676 shares, compared to its average volume of 990,877. Blueprint Medicines Co. has a twelve month low of $72.24 and a twelve month high of $121.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The company’s 50-day moving average price is $95.28 and its 200 day moving average price is $95.48. The firm has a market capitalization of $7.35 billion, a P/E ratio of -54.80 and a beta of 0.61.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same period in the prior year, the business posted ($2.20) EPS. The company’s revenue for the quarter was up 126.5% on a year-over-year basis. On average, equities research analysts forecast that Blueprint Medicines Co. will post -3.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Blueprint Medicines

Several institutional investors have recently made changes to their positions in BPMC. Quarry LP acquired a new stake in shares of Blueprint Medicines in the third quarter valued at about $32,000. R Squared Ltd purchased a new position in Blueprint Medicines in the fourth quarter valued at about $51,000. Covestor Ltd lifted its position in shares of Blueprint Medicines by 206.7% during the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 403 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Blueprint Medicines during the 3rd quarter valued at approximately $108,000. Finally, Values First Advisors Inc. purchased a new stake in shares of Blueprint Medicines during the 3rd quarter worth approximately $122,000.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BPMC. JMP Securities reissued a “market outperform” rating and issued a $125.00 price target on shares of Blueprint Medicines in a research note on Wednesday, January 15th. Wedbush reiterated an “outperform” rating and set a $124.00 price target (down from $135.00) on shares of Blueprint Medicines in a research note on Monday, January 13th. Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Finally, JPMorgan Chase & Co. assumed coverage on Blueprint Medicines in a research report on Thursday, November 14th. They set an “overweight” rating and a $126.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $122.72.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.